EGFR and head and neck squamous cell carcinoma: To explore EGFR/ERBB inhibitor-induced immune cell mobilization and therapeutic response in HNSCC patients, specimens were obtained from a completed neoadjuvant cetuximab trial (UPCI-08–013) entitled “Erbitux followed by Adjuvant treatment with chemoradiation and erbitux for locally advanced head and neck squamous cell carcinoma” (NCT01218048) [51].